• Publications
  • Influence
Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.
Dosimetry and biodistribution from this first trial suggest that phase II studies of 131I-TM-601 are indicated and may have an antitumoral effect in patients with recurrent glioma. Expand
Imaging glioma extent with 131I-TM-601.
131I-TM-601 provides a reliable estimate for primary tumor extent and further modification of this radiopeptide with other better imaging isotopes may provide an important tool for determining tumors extent and differentiating regions of viable tumor from necrosis. Expand
Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations.
In vivo results suggest that oligosaccharide modification of monoclonal antibodies is a preferred method of preparing conjugates, compared to more conventional methods. Expand
Radiation dosimetry of 131I-chlorotoxin for targeted radiotherapy in glioma-bearing mice
Dosimetry results of 131I-Chlorotoxin in athymic nude mice with intracranially implanted human glioma xenografts and projected radiation doses in patients receiving 370 MBq of 131i-Ch chlorotoxin demonstrated potential in improving patient survival using this novel targeting agent. Expand
Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled antibody.
Testing whether monoclonal antibodies labeled with 212Bi would be effective in treating peritoneal tumors showed that mice receiving the labeled antibody had a prolonged survival when compared to control mice. Expand
Thrombus imaging with technetium-99m synthetic peptides based upon the binding domain of a monoclonal antibody to activated platelets.
Using labeled synthetic peptides appears to be technically feasible but the absolute binding to thrombus is not yet sufficient for reliable imaging of pre-existing thrombi. Expand
Site-specifically modified 111In labelled antibodies give low liver backgrounds and improved radioimmunoscintigraphy.
Data indicate that modification of antibodies site-specifically at their oligosaccharide results in minimal non-specific uptake into non-target tissues and enhanced localization into the tumor target, and that this may represent a preferred method for production of 111In labelled antibodies. Expand
Site-specifically radioiodinated antibody for targeting tumors.
Labeling of an antibody site specifically through its carbohydrate regions preserves its antigen-binding activity (Rodwell et al., Proc. Natl. Acad. Sci., 83: 2632, 1986). Previously site-specificExpand